---
company: Merck & Co., Inc.
ticker: MRK
form: 8-K
filed: 2026-10-29
accepted: 2026-10-29T10:43:01+00:00
accession: 0001104659-26-119825
source: https://www.sec.gov/Archives/edgar/data/310158/000110465926119825/
---

# Merck (MRK) Q3 2026 earnings

## Header

- Company: Merck & Co., Inc.
- Reported: 2026-10-29 06:43 BMO ET
- Source: 8-K only — accession 0001104659-26-119825, Item 2.02 + Exhibit 99.1
- Verdict: GAAP EPS of $2.04 and non-GAAP EPS of $2.49 reflect a return to profitability after a Q2 loss, driven by operational strength and a lower effective tax rate, though operating expenses rose.

## Headline numbers

| Metric | Actual | YoY | QoQ | 8-K location |
|---|---:|---:|---:|---|
| Revenue | $16.61B | +5.0% | +0.2% | Ex. 99.1, Financial Summary |
| EPS (GAAP) | $2.04 | -12.0% | +3.78 | Ex. 99.1, Financial Summary |
| EPS (adjusted) | $2.49 | -3.5% | +2.62 | Ex. 99.1, Financial Summary |
| Net income | $5.07B | -12.0% | +6.40 | Ex. 99.1, Financial Summary |
| Adj. EBITDA | $6.16B | +4.8% | +7.49 | Ex. 99.1, Financial Summary |
| Adj. EBITDA margin | 37.1% | -0.8 pp | +1.1 pp | Ex. 99.1, Financial Summary |

## Revenue breakdown

not stated in the 8-K

## Margins and costs

- Gross margin: 72.9% (prior 77.7%, change -4.8 pp)
- Operating expenses: $9.7B (+7% YoY)
- One-offs in the quarter: SciBrunch license agreement: $0.12 per share; Restructuring costs: $184M; Acquisition- and divestiture-related costs: $1.17B
- Effective tax rate: 8.9% (prior-year 14.2%, year-to-date 138.2%)
- Non-GAAP bridge: Excludes acquisition- and divestiture-related costs, restructuring costs, and income/losses from equity securities.

## KPIs

| Metric | Actual | Prior quarter | Prior year | Change |
|---|---:|---:|---:|---:|
| Effective income tax rate | 8.9% | -95.9% | 14.2% | -106.1 pp |
| Non-GAAP effective income tax rate | 10.9% | 160.3% | 13.4% | -102.4 pp |

## Guidance

| Metric | Guide | Prior guide | Change |
|---|---:|---:|---|
| Full-year 2026 sales | $66.8B - $67.3B | $66.3B - $67.3B | Narrowed and raised |
| Full-year 2026 non-GAAP EPS | $2.77 - $2.82 | $2.66 - $2.76 | Raised |
| Full-year 2026 non-GAAP effective income tax rate | 32.0% - 33.0% | 35.0% - 36.0% | Lowered |

## What drove it

- Revenue story: Sales grew 5.0% year-over-year, driven by continued strength in Oncology and Animal Health, plus contributions from other products including WINREVAIR.
- EPS story: EPS moved from a loss in Q2 to earnings in Q3, driven by operational strength and a lower effective tax rate, partially offset by higher operating expenses and amortization.
- One-off check: SciBrunch license agreement: $0.12 per share (one-time charge).

## The good

- Return to GAAP profitability ($2.04 EPS).
- Lower effective income tax rate (8.9%).
- Revenue growth of 5.0% year-over-year.
- Guidance raised for full-year non-GAAP EPS and sales.

## The bad

- Non-GAAP EPS decreased 3.5% year-over-year.
- Higher operating expenses (+7% YoY).
- Gross margin decreased 4.8 percentage points year-over-year.

## The ugly

- none

## Open questions

- The release references 'positive momentum across multiple therapeutic areas' and 'practice-changing advances' but does not provide specific sales figures for Oncology or Animal Health segments.
- The filing mentions a 'lower effective income tax rate' driven by 'favorable impacts of certain discrete items' but does not quantify these items.

## Full release

### Earnings: MRK — filed 2026-10-29

Merck & Co., Inc. (MRK) · Form 8-K, Item 2.02 · Filed 2026-10-29 · [SEC filing](https://www.sec.gov/Archives/edgar/data/310158/000110465926119825/)

- 1 -

Merck & Co., Inc., Rahway, N.J.,

USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline

Sales Growth Reflects Continued Strength in

Oncology and Animal Health, Plus Contributions From Other Products in Broader Portfolio, Including WINREVAIR

Financial Highlights

Pipeline & Portfolio Highlights

Full-Year 2026 Financial Outlook¹

Available in some markets as KEYTRUDA SC.

- 2 -

RAHWAY, N.J., Oct. 29, 2026 – Merck & Co., Inc.,

Rahway, N.J., USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2026.

“Our science-led strategy is transforming our business,” said Robert M. Davis, chairman and chief executive officer. “The potentially practice-changing advances in oncology presented at last weekend’s ESMO meeting, including new data for our antibody-drug conjugate sac-TMT and the first Phase

3 validation of a therapeutic cancer vaccine, further clinically de-risk the substantial long-term opportunity of our late-phase pipeline.

With positive momentum across multiple therapeutic areas, I’m increasingly confident in our ability to deliver long-term value for patients and shareholders.”

Financial Summary

*Refer to table on page 7.

For the third quarter of 2026, Generally Accepted

Accounting Principles (GAAP) earnings per share (EPS) assuming dilution was $2.04 and non-GAAP EPS was $2.49. Both GAAP and non-GAAP

EPS in the third quarter of 2026 include a one-time charge of $0.12 per share related to a global license agreement with SciBrunch Therapeutics

Co., Ltd. (SciBrunch). Both GAAP and non-GAAP EPS in the third quarter of 2025 include a charge of $0.10 per share for a milestone payment to LaNova Medicines Ltd. (LaNova, acquired by Sino Biopharmaceutical Limited) associated with the technology transfer for MK-2010.

Non-GAAP EPS excludes acquisition- and divestiture-related costs and costs related to restructuring programs, as well as income and losses from investments in equity securities. Non-GAAP EPS in the third quarter of 2025 also excludes tax expense relating to audit reserve adjustments.²

Net income attributable to the Company.³

The Company is providing certain 2026 and 2025 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the Company’s results because management uses non-GAAP results to assess performance.

Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to this release.

- 3 -

Year-to-date results can be found in the attached tables.

Third-Quarter Sales Performance

The following table reflects sales of the Company’s top products and significant performance drivers.

- 4 -

*Alliance revenue for this product represents the

Company’s share of profits, which are product sales net of cost of sales and commercialization costs.

**Other revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities.

In addition, Koselugo alliance revenue was $13 million in the third quarter of 2026 compared with $214 million in the third quarter of 2025. The decrease was due to an amendment to the collaboration agreement with AstraZeneca in 2025, which discontinued the provisions whereby the Company shared revenue and costs with AstraZeneca, and revised the payment structure, resulting in the Company’s recognition of a $150 million upfront payment and a $50 million regulatory milestone in the third quarter of 2025.

- 5 -

Third-Quarter Expense and Related Information

The table below presents selected expense information.

GAAP Expense, EPS and Related Information

Gross margin was 72.9% for the third quarter of

2026 compared with 77.7% for the third quarter of 2025. The decrease was primarily due to higher amortization of intangible assets, restructuring costs and production costs.

Selling, general and administrative (SG&A) expenses were $2.9 billion in the third quarter of 2026, an increase of 10% compared with the third quarter of 2025. The increase was primarily due to higher administrative costs, as well as higher promotional costs in support of product launches.

Research and development (R&D) expenses were

$4.5 billion in the third quarter of 2026, an increase of 7% compared with the third quarter of 2025. The increase was primarily due to a $400 million charge related to a global license agreement with SciBrunch and higher clinical development spending, partially offset by lower restructuring costs and a $200 million reduction in R&D expenses as part of a funding agreement with Blackstone Life Sciences

(Blackstone). R&D expenses in the third quarter of 2025 include a $300 million charge for a milestone payment to LaNova for the completion of the technology transfer for MK-2010.

Other (income) expense, net, was $27 million of expense in the third quarter of 2026 compared with $238 million of income in the third quarter of 2025. The unfavorability was primarily due to higher net interest expense.⁴... (truncated)mortization of intangible assets, intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Also includes integration, transaction and certain other costs associated with acquisitions and divestitures, as well as amortization of intangible assets related to collaborations, licensing arrangements and asset acquisitions, and recognition of fair value step-up to inventories for asset acquisitions.

- 6 -

The effective income tax rate for the third quarter of 2026 was 8.9%, reflecting the favorable impacts of certain discrete items, as well as jurisdictional mix of income and expense.

GAAP EPS was $2.04 for the third quarter of 2026 compared with $2.32 for the third quarter of 2025. The decrease was primarily driven by higher operating expenses, reflecting increased investments to advance the R&D pipeline and support product launches, higher amortization of intangible assets, higher net interest expense and increased restructuring costs, partially offset by operational strength in the business and a lower effective income tax rate.

Non-GAAP Expense, EPS and Related Information

Non-GAAP gross margin was 81.4% for the third quarter of 2026 compared with 81.9% for the third quarter of 2025. The decrease was primarily due to higher production costs.

Non-GAAP SG&A expenses were $2.9 billion in the third quarter of 2026, an increase of 10% compared with the third quarter of 2025. The increase was primarily due to higher administrative costs, as well as higher promotional costs in support of product launches.

Non-GAAP R&D expenses were $4.5 billion in the third quarter of 2026, an increase of 13% compared with the third quarter of 2025. The increase was primarily due to a $400 million charge related to a global license agreement with SciBrunch and higher clinical development spending, partially offset by a $200 million reduction in R&D expenses as part of a funding agreement with Blackstone. R&D expenses in the third quarter of 2025 include a

$300 million charge for a milestone payment to LaNova for the completion of the technology transfer for MK-2010.

Non-GAAP other (income) expense, net, was $420 million of expense in the third quarter of 2026 compared with $106 million of expense in the third quarter of 2025. The unfavorability was primarily due to higher net interest expense.

The non-GAAP effective income tax rate for the third quarter of 2026 was 10.9%, reflecting the favorable impacts of certain discrete items, as well as jurisdictional mix of income and expense.

Non-GAAP EPS was $2.49 for the third quarter of

2026 compared with $2.58 for the third quarter of 2025. The decrease was primarily driven by higher operating expenses, reflecting increased investments to advance the R&D pipeline and support product launches, and higher net interest expense, partially offset by operational strength in the business and a lower effective income tax rate.

- 7 -

A reconciliation of GAAP to non-GAAP net income and EPS is provided in the table that follows.

Pipeline and Portfolio Highlights

In the third quarter, the Company achieved key regulatory and clinical milestones to meaningfully advance its broad and diverse pipeline.⁵

Includes the estimated income tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments for all periods presented. Amount in the third quarter of 2025 also includes $86 million of tax expense relating to audit reserve adjustments.

- 8 -

- 9 -

Notable recent news releases on the Company’s pipeline and portfolio are provided in the table that follows. Visit the News Releases section of the Company’s website to read the releases.*

- 10 -

*References in the above news release titles have been modified for the purpose of this announcement.

Sustainability Highlights

The Company’s 2025/2026 Purpose for Progress

Impact Report provided a comprehensive view of the Company’s measurable progress across its sustainability priorities, including achieving all goals targeted for completion by 2025. The Company also introduced new targets for 2030, including a goal to reach

100 million people with access solutions that close gaps in care by 2030.

Full-Year 2026 Financial Outlook

The following table summarizes the Company’s full-year financial outlook.

*The Company does not have any non-GAAP adjustments to sales.

**Includes one-time R&D charges of $9.0 billion for the acquisition of Cidara Therapeutics, Inc. (Cidara), $5.7 billion for the acquisition of Terns Pharmaceuticals, Inc.

(Terns), and $400 million related to the global license agreement with SciBrunch. Outlook does not assume any additional significant potential business development transactions.

***Includes one-time charges of $3.62 per share for the acquisition of Cidara, $2.31 per share for the acquisition of Terns, and $0.12 per share related to the global license agreement with SciBrunch.

The Company has not provided a reconciliation of forward-looking non-GAAP gross margin, non-GAAP operating expenses, non-GAAP other (income) expense, net, non-GAAP effective income tax rate and non-GAAP EPS to the most directly comparable GAAP measures, given it cannot predict with reasonable certainty the amounts necessary for such a reconciliation, including intangible asset impairment charges, legal settlements, and income and losses from investments in equity securities either owned directly or through ownership interests in investment funds, without unreasonable effort. These items are inherently difficult to forecast and could have a significant impact on the Company’s future GAAP results.

- 11 -... (truncated)sales to be between $66.8 billion and $67.3 billion, including a positive impact from foreign exchange of approximately 1% at mid-October 2026 exchange rates.

The Company now expects the full-year non-GAAP effective income tax rate to be between 32.0% and 33.0%, including the impact of the non-tax-deductible one-time charges for the acquisitions of Cidara and Terns.

The Company now expects full-year 2026 non-GAAP

EPS to be between $2.77 and $2.82, including a positive impact from foreign exchange of approximately $0.15 per share at mid-October 2026 exchange rates. This range includes one-time charges of $9.0 billion, or $3.62 per share, related to the acquisition of Cidara; $5.7 billion, or $2.31 per share, related to the acquisition of Terns; and $400 million, or $0.12 per share, related to the global license agreement with SciBrunch. The charge related to SciBrunch was not previously included in the outlook. In 2025, non-GAAP EPS of $8.98 was negatively impacted by one-time charges of $0.20 per share in the aggregate related to certain business development transactions.

Consistent with past practice, the financial outlook does not assume additional significant potential business development transactions.

Earnings Conference Call

Investors, journalists and the general public may access a live audio webcast of the call on Thursday, Oct. 29, at 9 a.m. EDT via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available on the Company’s website.

All participants may join the call by dialing

(800) 369-3351 (U.S. and Canada Toll-Free) or (517) 308-9448 and using the access code 9818590.

About Our Company

At Merck & Co., Inc., Rahway, N.J.,

USA, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.

- 12 -

Forward-Looking Statement of Merck & Co., Inc., Rahway,

N.J., USA

This news release of Merck & Co., Inc.,

Rahway, N.J., USA (the “Company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful.

If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the Company’s Annual

Report on Form 10-K for the year ended December 31, 2025 and the Company’s other filings with the Securities and Exchange

Commission (SEC) available at the SEC’s Internet site ( www.sec.gov).

Appendix

Generic product names are provided below.

Pharmaceutical

BRIDION

(sugammadex)

CAPVAXIVE

(Pneumococcal 21-valent Conjugate Vaccine)

ENFLONSIA

(clesrovimab-cfor)

GARDASIL

(

Human Papillomavirus Quadrivalent [Types

6, 11, 16 and 18] Vaccine, Recombinant)

GARDASIL 9

(Human Papillomavirus 9-valent Vaccine, Recombinant)

IDVYNSO

(doravirine/islatravir)

JANUMET

(sitagliptin and metformin HCl)

JANUVIA

(sitagliptin)

KEYTRUDA

(pembrolizumab)

KEYTRUDA QLEX

(pembrolizumab and berahyaluronidase alfa-pmph)

- 13 -

LAGEVRIO

(molnupiravir)

Lenvima

(lenvatinib)

Lynparza

(olaparib)

M-M-R II

(Measles, Mumps and Rubella Virus Vaccine Live)

OHTUVAYRE

(ensifentrine)

PREVYMIS

( letermovir)

PROQUAD

(Measles, Mumps, Rubella and Varicella Virus Vaccine Live)

VARIVAX

(Varicella Virus Vaccine Live)

WELIREG

( belzutifan)

WINREVAIR

(sotatercept-csrk)

Animal Health

BRAVECTO

(fluralaner)

###

MERCK

& CO., INC., RAHWAY, N.J., USA

#### Financial statements

##### Income Statement (Table 1a)

| | 2026 – 1Q | 2026 – 2Q | 2026 – 3Q | 2026 – Sep YTD | 2025 – 1Q | 2025 – 2Q | 2025 – 3Q | 2025 – Sep YTD | 2025 – 4Q | 2025 – Full Year | % Change – 3Q | % Change – Sep YTD |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| Sales | 16,286 | 16,607 | 18,085 | 50,978 | 15,529 | 15,806 | 17,276 | 48,611 | 16,400 | 65,011 | 5.0% | 5.0% |
| **Costs, Expenses and Other** | | | | | | | | | | | | |
| Cost of sales | 4,195 | 4,395 | 4,892 | 13,482 | 3,419 | 3,557 | 3,855 | 10,831 | 5,551 | 16,382 | 27.0% | 24.0% |
| Selling, general and administrative | 2,700 | 2,904 | 2,886 | 8,491 | 2,552 | 2,649 | 2,633 | 7,835 | 2,898 | 10,733 | 10.0% | 8.0% |
| Research and development | 12,592 | 9,741 | 4,537 | 26,871 | 3,621 | 4,048 | 4,234 | 11,903 | 3,886 | 15,789 | 7.0% |  |
| Restructuring costs | 195 | 151 | 184 | 530 | 69 | 560 | 47 | 676 | 213 | 889 |  | -22.0% |
| Other (income) expense, net | 138 | 99 | 27 | 262 | -35 | -7 | -238 | -281 | 432 | 151 |  |  |
| (Loss) Income Before Taxes | -3,534 | -683 | 5,559 | 1,342 | 5,903 | 4,999 | 6,745 | 17,647 | 3,420 | 21,067 | -18.0% | -92.0% |
| Income Tax Provision | 709 | 654 | 492 | 1,855 | 818 | 571 | 958 | 2,346 | 458 | 2,804 |  |  |
| Net (Loss) Income | -4,243 | -1,337 | 5,067 | -513 | 5,085 | 4,428 | 5,787 | 15,301 | 2,962 | 18,263 | -12.0% |  |
| Less: Net (Loss) Income Attributable to Noncontrolling Interests | -3 | -2 | 2 | -3 | 6 | 1 | 2 | 10 | -1 | 9 |  |  |
| Net (Loss) Income Attributable to Merck & Co., Inc., Rahway, N.J., USA | -4,240 | -1,335 | 5,065 | -510 | 5,079 | 4,427 | 5,785 | 15,291 | 2,963 | 18,254 | -12.0% |  |
| (Loss) Earnings per Common Share Assuming Dilution (1) | -1.72 | -0.54 | 2.04 | -0.21 | 2.01 | 1.76 | 2.32 | 6.08 | 1.19 | 7.28 | -12.0% |  |
| Average Shares Outstanding Assuming Dilution (1) | 2,472 | 2,470 | 2,478 | 2,471 | 2,531 | 2,513 | 2,498 | 2,514 | 2,488 | 2,507 |  |  |
| Effective Income Tax Rate | -20.1% | -95.9% | 8.9% | 138.2 | 13.9% | 11.4% | 14.2% | 13.3% | 13.4% | 13.3 |  |  |

##### Income Statement (Table 1a (in millions))

| | GAAP | Acquisition- and Divestiture-Related Costs (1) | Restructuring Costs (2) | (Income) Loss from Investments in Equity Securities | Certain Other Items | Adjustment Subtotal | Non-GAAP |
|---|---:|---:|---:|---:|---:|---:|---:|
| **Third Quarter** | | | | | | | |
| Cost of sales | 3,855 | 621 | 110 |  |  | 731 | 3,124 |
| Selling, general and administrative | 2,633 | 34 |  |  |  | 34 | 2,599 |
| Research and development | 4,234 | 4 | 233 |  |  | 237 | 3,997 |
| Restructuring costs | 47 |  | 47 |  |  | 47 |  |
| Other (income) expense, net | -238 |  |  | -344 |  | -344 | 106 |
| Income Before Taxes | 6,745 | -659 | -390 | 344 |  | -705 | 7,450 |
| Income Tax Provision (Benefit) | 958 | -3 | -3 | -3 | -4 | -42 | 1,000 |
| Net Income | 5,787 | -540 | -308 | 271 | -86 | -663 | 6,450 |
| Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA | 5,785 | -540 | -308 | 271 | -86 | -663 | 6,448 |
| Earnings per Common Share Assuming Dilution | 2.32 | -0.22 | -0.12 | 0.11 | -0.03 | -0.26 | 2.58 |
| Effective Income Tax Rate | 14.2% |  |  |  |  |  | 13.4 |
| **September YTD** | | | | | | | |
| Cost of sales | 10,831 | 1,817 | 311 |  |  | 2,128 | 8,703 |
| Selling, general and administrative | 7,835 | 72 | 1 |  |  | 73 | 7,762 |
| Research and development | 11,903 | 14 | 286 |  |  | 300 | 11,603 |
| Restructuring costs | 676 |  | 676 |  |  | 676 |  |
| Other (income) expense, net | -281 | -3 |  | -512 |  | -515 | 234 |
| Income Before Taxes | 17,647 | -1,900 | -1,274 | 512 |  | -2,662 | 20,309 |
| Income Tax Provision (Benefit) | 2,346 | -3 | -3 | -3 | -4 | -528 | 2,874 |
| Net Income | 15,301 | -1,562 | -1,035 | 403 | 60 | -2,134 | 17,435 |
| Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA | 15,291 | -1,562 | -1,035 | 403 | 60 | -2,134 | 17,425 |
| Earnings per Common Share Assuming Dilution | 6.08 | -0.62 | -0.41 | 0.16 | 0.02 | -0.85 | 6.93 |
| Effective Income Tax Rate | 13.3% |  |  |  |  |  | 14.2 |

##### Income Statement (Acquisition- and Divestiture- Related Costs4 — The table below presents selected expense information. (in millions))

| | Third Quarter 2026 – GAAP | Third Quarter 2026 – Acquisition- and Divestiture- Related Costs4 | Third Quarter 2026 – Restructuring Costs | Third Quarter 2026 – (Income) Loss From Investments in Equity Securities | Third Quarter 2026 – Non- GAAP3 |
|---|---:|---:|---:|---:|---:|
| Cost of sales | 4,892 | 1,140 | 396 |  | 3,356 |
| Selling, general and administrative | 2,886 | 24 |  |  | 2,862 |
| Research and development | 4,537 | 3 | 1 |  | 4,533 |
| Restructuring costs | 184 |  | 184 |  |  |
| Other (income) expense, net | 27 |  |  | -393 | 420 |
| **Third Quarter 2025** | | | | | |
| Cost of sales | 3,855 | 621 | 110 |  | 3,124 |
| Selling, general and administrative | 2,633 | 34 |  |  | 2,599 |
| Research and development | 4,234 | 4 | 233 |  | 3,997 |
| Restructuring costs | 47 |  | 47 |  |  |
| Other (income) expense, net | -238 |  |  | -344 | 106 |

##### Income Statement (Third Quarter — A reconciliation of GAAP to non-GAAP net income and EPS is provided in the table that follows. (in millions))

| | Third Quarter – 2026 | Third Quarter – 2025 |
|---|---:|---:|
| **EPS** | | |
| GAAP EPS | 2.04 | 2.32 |
| Difference | 0.45 | 0.26 |
| Non-GAAP EPS that excludes items listed below3 | 2.49 | 2.58 |
| **Net Income** | | |
| GAAP net income2 | 5,065 | 5,785 |
| Difference | 1,094 | 663 |
| Non-GAAP net income that excludes items listed below2,3 | 6,159 | 6,448 |
| **Excluded Items:** | | |
| Acquisition- and divestiture-related costs4 | 1,167 | 659 |

##### Income Statement (Table 1 (in millions))

| | GAAP – 3Q26 | GAAP – 3Q25 | % Change | GAAP – Sep YTD 2026 | GAAP – Sep YTD 2025 | % Change |
|---|---:|---:|---:|---:|---:|---:|
| Sales | 18,085 | 17,276 | 5.0% | 50,978 | 48,611 | 5.0% |
| **Costs, Expenses and Other** | | | | | | |
| Cost of sales | 4,892 | 3,855 | 27.0% | 13,482 | 10,831 | 24.0% |
| Selling, general and administrative | 2,886 | 2,633 | 10.0% | 8,491 | 7,835 | 8.0% |
| Research and development | 4,537 | 4,234 | 7.0% | 26,871 | 11,903 |  |
| Restructuring costs | 184 | 47 |  | 530 | 676 | -22.0% |
| Other (income) expense, net | 27 | -238 |  | 262 | -281 |  |
| Income Before Taxes | 5,559 | 6,745 | -18.0% | 1,342 | 17,647 | -92.0% |
| Income Tax Provision | 492 | 958 |  | 1,855 | 2,346 |  |
| Net Income (Loss) | 5,067 | 5,787 | -12.0% | -513 | 15,301 |  |
| Less: Net Income (Loss) Attributable to Noncontrolling Interests | 2 | 2 |  | -3 | 10 |  |
| Net Income (Loss) Attributable to Merck & Co., Inc., Rahway, N.J., USA | 5,065 | 5,785 | -12.0% | -510 | 15,291 |  |
| Earnings (Loss) per Common Share Assuming Dilution (1) | 2.04 | 2.32 | -12.0% | -0.21 | 6.08 |  |
| Average Shares Outstanding Assuming Dilution (1) | 2,478 | 2,498 |  | 2,471 | 2,514 |  |
| Effective Income Tax Rate | 8.9 | 14.2% |  | 138.2 | 13.3% |  |
